Overview

A class action lawsuit has been filed against Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE : BSX) and certain of the Company’s senior executive officers (collectively, “Defendants”), alleging violations of the federal securities laws. The Boston Scientific lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Boston Scientific common stock between July 23, 2025, and February 3, 2026, inclusive (the “Class Period”). Investors have until May 4, 2026, to seek appointment as lead plaintiff of the Boston Scientific class action lawsuit.

Boston Scientific manufactures and markets medical devices used across various specialties. In pertinent part, the Company has an Electrophysiology (“EP”) business unit that develops and manufactures products used in the detection and treatment of heart rate and rhythm disorders.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and omitted material information concerning Boston Scientific’s growth and competitive position, particularly with respect to the Company’s U.S. EP business. According to the complaint, Defendants expressed confidence in the sustainability of the EP segment’s growth and repeatedly raised or reaffirmed guidance while highlighting the segment’s performance and future growth potential.

In truth, Boston Scientific’s ambition of continuing “to grow our share in the overall EP market” to maintain a growth trajectory at “2x the market” had fallen short of reality; the Company had begun to experience new competition entrants that were sapping Boston Scientific’s U.S. Electrophysiology market share and thus limiting the Company’s growth potential.

The truth was revealed on February 4, 2026, when Boston Scientific issued financial results for the fourth quarter and full year of 2025, announcing disappointing U.S. EP sales and guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and poor guidance to a combination of slower than expected market growth alongside increased competition, despite management’s previous claims of a “growing” EP business and assertions they “have a very good understanding of what competition we will face and in what time frame.”

On this news, the price of Boston Scientific’s common stock declined dramatically. The Company’ stock price fell $16.12 per share, or more than 17%, from a closing market price of $91.62 per share on February 3, 2026, to close at $75.50 per share on February 4, 2026.

*          *          *

If you purchased or otherwise acquired Boston Scientific common stock between July 23, 2025, and February 3, 2026, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Boston Scientific class action lawsuit is May 4, 2026.